Analyst Ratings for Acadia Pharmaceuticals (ACAD)
ACAD Rating Summary
ACAD Price Target Summary
- Highest: $40.00 (UBS)
- Lowest: $15.00 (Goldman Sachs)
- Average: $30.05
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$30.05 (+35.6%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 58%
Avg. $ Target:
$30.05 (+35.6%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 58%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2026 | Wolfe Research | Rudy Li | New Coverage | Outperform (N/A) |
33.00 (N/A) |
23.99 (22.16) |
-7.63% | Details |
| 2/23/2026 | Mizuho | Uy Ear | Upgrade | Outperform (Neutral) |
35.00 (29.00) |
24.33 (22.16) |
-8.92% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
